Peramivir

I think I have the flu. Should I ask my GP for antivirals?

Retrieved on: 
Tuesday, August 29, 2023

If you test positive for COVID and you’re eligible for antivirals, you’ll likely ask your GP for a script to protect you from severe disease.

Key Points: 
  • If you test positive for COVID and you’re eligible for antivirals, you’ll likely ask your GP for a script to protect you from severe disease.
  • So when should you make the effort to see a GP for a prescription for influenza antivirals?

What exactly is influenza?


    The flu is primarily a viral infection of the respiratory system that can spread through sneezing, coughing, or touching contaminated objects then touching your nose or mouth. Common symptoms include headache, sore throat, fever, runny or blocked nose and body aches that last a week or more. Influenza is actually a group of viruses, divided into several sub-groups. Flu A and B are the most common groups that circulate in humans.

What are flu antivirals?

    • Most flu antivirals target neuraminidase, an important enzyme the virus uses to release itself from cells.
    • On the other hand, COVID antivirals work by inhibiting other parts of the viral life cycle involved in the virus replicating itself.
    • Read more:
      Should I get a flu vaccine this year?

How effective are antivirals for the flu?

    • Antivirals have the greatest effect if started 24-72 hours after symptoms.
    • In a study from the 2009 swine flu (H1N1) pandemic in the United States, treatment with antivirals (Tamiflu and Relenza) reduced the chance of needing to be hospitalised.
    • The research is less clear about whether antivirals prevent the development of flu complications such as secondary bacterial pneumonia.

Are flu antivirals becoming less effective?

    • The impact of the antiviral resistance is unclear but there is evidence indicating resistant strains can uphold their ability to replicate effectively and spread.
    • However, government agencies and surveillance programs are constantly monitoring the spread of antiviral resistance.

Antivirals can also prevent the flu if you’ve been exposed

    • Tamiflu and Relenza can also be used to prevent flu infections, if we’re exposed to the virus or come into contact with infected people.
    • Some studies suggest Tamiflu and Relenza can reduce the chance of developing symptomatic influenza by 70-90%.

So who should talk to their GP about a prescription?


    Australian guidelines recommend doctors offer antivirals to people with influenza who have severe disease or complications. Doctors can also consider treatment for people at higher risk of developing severe disease from influenza. This includes:
    • Antiviral treatment also can be considered for otherwise healthy symptomatic patients who have confirmed or suspected influenza, if they can start treatment within 48 hours of developing symptoms.
    • In some instances a doctors can make a clinical diagnosis of influenza based on the symptoms and known close flu positive contacts of the patient.
    • Read more:
      What happens in our body when we encounter and fight off a virus like the flu, SARS-CoV-2 or RSV?

BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

Retrieved on: 
Tuesday, February 21, 2023

RESEARCH TRIANGLE PARK, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.

Key Points: 
  • ORLADEYO net revenue in the fourth quarter of 2022 was $70.7 million.
  • New patient demand for ORLADEYO was strong in the fourth quarter, consistent with the steady growth trajectory observed since launch.
  • Selling, general and administrative (SG&A) expenses for the fourth quarter of 2022 increased to $50.2 million, compared to $35.4 million in the fourth quarter of 2021 (+42 percent year-over-year).
  • Interest expense was $26.5 million in the fourth quarter of 2022, compared to $18.8 million in the fourth quarter of 2021.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, August 3, 2021

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 5, 2021

b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.
  • ET and the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m.
  • ET.
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Report First Quarter 2021 Financial Results on May 6

Retrieved on: 
Thursday, April 22, 2021

b'RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.\nBioCryst management will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.\nBioCryst management will host a conference call and webcast at 8:30 a.m.
  • ET that day to discuss the financial results and provide a corporate update.\nThe live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 2660434.
  • A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com .
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB(peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the companys website at www.biocryst.com .

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, February 2, 2021

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, January 7, 2021

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 6, 2021

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the Companys website at www.biocryst.com.

BioCryst to Present at JMP Securities Hematology Summit

Retrieved on: 
Friday, December 11, 2020

RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB(peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCrysts first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the Companys website at www.biocryst.com .